Innovent Biologics, Inc. · HKEX:1801

Innovent Biologics — Morgan Stanley's 22nd Annual Asia Pacific Summit (November 2023)

33 slides from Innovent Biologics's conference presentation, Nov 15, 2023

  1. Slide 1: Where are the new opportunities of innovation: new modalities and emerging therapeutic areas

    Where are the new opportunities of innovation: new modalities and emerging therapeutic areas Michael Yu, Ph.D., Founder, Chairman and CEO of Innovent Biologics, Inc. November 15, 2023 Singapore

  2. Slide 2: New Opportunities of Global Biopharma Industry

    New Opportunities of Global Biopharma Industry 2

  3. Slide 3: Global biopharma industry: new modalities and breakthrough for chronic diseases have created significant opportunities

    Global biopharma industry: new modalities and breakthrough for chronic diseases have created significant opportunities New Modalities Chronic Diseases mAb, ADC, BsAb, Peptides, CGT, Nucleic Acids, PROTAC…. Diabetes, Obesity, Heart Disease, Alzheimer’s, Arthritis… BCG forecast: 5yr forward projected

  4. Slide 4: ……and drives the stock market enthusiasm

    ……and drives the stock market enthusiasm Selected best performing biotech/pharmaceutical stocks in the past five years (by market capitalization, USD Bn) 1 118 +367% Therapeutic breakthrough in 551 diabetes, obesity, Alzheimer’s disease and hematology… 105 +332% 456 2 8 Pioneering technology platfor

  5. Slide 5: Innovation from China: innovation strength getting recognized through increasing cross-border out-licensing deals

    Innovation from China: innovation strength getting recognized through increasing cross-border out-licensing deals East to West Deals: Licensor Location (Jan 22 to Aug 23) Deal Flow Between China and the West S.Korea 15% 13% 31% 24% Japan 8% 37% China to West 14% West to China 85% 87% 69% 76% 63% 78%

  6. Slide 6: New modalities: oncology is the primary licensing area from China to global

    New modalities: oncology is the primary licensing area from China to global, among which antibody plus ADC account for 50%+ Cancer modalities Immune cell Vaccine BsAb 4% 4% 5% CAR-T Antibody 6% 30% 23% ADC 29% Small molecule Confidential Copyright© 2023 Innovent 6

  7. Slide 7: ADC: has emerged as one of the forefront modalities in the past few years

    ADC: has emerged as one of the forefront modalities in the past few years 1881 1903 1949 1997-now Surgery Radiotherapy Chemotherapy The first successful surgery The first successful use of The first chemotherapy drug— performed for stomach cancer radiation to cure skin cancer nitrogen mustard approv

  8. Slide 8: ADC: is still at early stage of development; will win the future with next-generation ADCs

    ADC: is still at early stage of development; will win the future with next-generation ADCs Novel Cytotoxic Immune-Stimulating Novel Target Bispecific ADC Fragment ADC agents Payload • Broader therapeutic • More selective tumor • Reduced off-target • Immune agonist as • Fragment ADCs such as targets

  9. Slide 9: ADC: is positioned for substantial growth in the next decade

    ADC: is positioned for substantial growth in the next decade ADC is projected to be a huge new opportunity ADC multi-billion blockbusters keep setting new sales records Projected Global Drug Market Segments 2021-2030E USD Bn Antibody 400 (HER2 ADC) (CD30 ADC) +7% 2022 sales: USD ~2.3bn 2022 sales: U

  10. Slide 10: Chronic diseases: huge market potential lies beyond oncology in cardiovascular and metabolism (CVM)

    Chronic diseases: huge market potential lies beyond oncology in cardiovascular and metabolism (CVM) Main therapeutic areas’ market size & growth trends globally by 2030E Oncology Immunology Cardiovascular Metabolism USD Bn 500 500 500 500 250 250 250 250 450 200 300 200 200 125 100 100 0 0 0 0 2022

  11. Slide 11: Obesity: GLP-1 drugs will reshape treatment of obesity and even other diseases

    Obesity: GLP-1 drugs will reshape treatment of obesity and even other diseases Obesity: a gateway disease associated with serious health GLP-1 class broke through the status quo of no effective conditions and decreased life expectancy medicines since 2021 with unprecedented efficacy metabolic mechan

  12. Slide 12: Anti-obesity drugs: are anticipated to have huge market potential

    Anti-obesity drugs: are anticipated to have huge market potential and even long-term implications to the economy US China ~100 million ~160 million People living with obesity $70-billion $200 Market value estimates Confidential Copyright© 2023 Innovent 12

  13. Slide 13: Innovent Biologics: Beyond China and Oncology

    Innovent Biologics: Beyond China and Oncology 13

  14. Slide 14: With established integrated platform, Innovent continues the journey to a global biopharmaceutical company

    With established integrated platform, Innovent continues the journey to a global biopharmaceutical company First 12 years of history, Innovent becomes a leading fully-integrated biopharmaceutical company in China 10 24 140,000L 30 6,000 Commercial products Clinical stage candidates Capacity in opera

  15. Slide 15: Innovent has established a leading position in oncology in China

    Innovent has established a leading position in oncology in China Achieved over Rmb4.1bn product revenue in 9M23 with accelerated growth Commercial portfolio expanded to ten products Accelerated Product Revenue Growth in 2023 ✓ Two new products approved in 2023 ✓ 8 in oncology, 1 in autoimmune, 1 in

  16. Slide 16: CVM will be another strategic growth driver in the next 5 years

    CVM will be another strategic growth driver in the next 5 years Portfolio potential to Rmb20bn by 2027 GLP-1R/GCGR IL-23 p19 IGF-1R XOI RMB 20bn PDE4 Annual Domestic Sales in 2027 VEGF/C KRASG12C ROS1 CTLA-4 4.1 bn 9M2023 CEACAM5 SINTBILO® (PCSK9) 20 approved assets FUCASO® (BCMA CAR-T) BIC/FIC Inno

  17. Slide 17: Pipeline strategy for CVM: build a strong franchise with mazdutide as the cornerstone asset

    Pipeline strategy for CVM: build a strong franchise with mazdutide as the cornerstone asset Develop Pipeline of Blockbusters and Next-gen Innovation Huge Market Potential and Significant Unmet Needs Oral delivery ~USD 500B ~1Bn ppl CVM global market by 2030 People living with obesity SINTBILO® (PCSK

  18. Slide 18: Mazdutide: globally first GLP-1R/GCGR dual agonist with unique MOAs

    Mazdutide: globally first GLP-1R/GCGR dual agonist with unique MOAs Potentially BIC therapy for obesity and diabetes, the 4th Phase 3 trial to be initiated soon Mazdutide can increase energy expenditure as additional benefit Mazdutide development overview Energy intake Energy expenditure Ph2 Ph3 NDA

  19. Slide 19: Mazdutide: superior weight loss efficacy to other GLP-1 drugs

    Mazdutide: superior weight loss efficacy to other GLP-1 drugs Summary of weight reduction in major GLP-1 class drugs in 48 weeks 48-week mean body weight reduction% (indirect comparison, placebo-adjusted) Global population oriented trials Chinese population oriented trials Mean BMI (kg/m2) 38.3 37.9

  20. Slide 20: Mazdutide: differentiated benefits observed as a GLP-1R/GCGR dual agonist

    Mazdutide: differentiated benefits observed as a GLP-1R/GCGR dual agonist Metabolic benefits summary of mazdutide sUA Liver fat • Corresponding to changes in body weight, the mean waist circumference and blood pressure of subjects in Liver the mazdutide group decreased. Blood glucose* Waist circumst

  21. Slide 21: Mazdutide: differentiated metabolic benefits when compared to other GLP-1 drugs

    Mazdutide: differentiated metabolic benefits when compared to other GLP-1 drugs Significantly reduced liver fat content, ALT, AST and sUA levels 73% liver fat content reduction Significant ALT and AST levels reduction Significant sUA level reduction Mean liver fat content change (%) Mean ALT change

  22. Slide 22: Mazdutide: favorable tolerability and safety profile when compared to other GLP-1s

    Mazdutide: favorable tolerability and safety profile when compared to other GLP-1s SAE and AE-led drop-out in major GLP-1 class drugs Serious adverse events % during treatment (indirect comparison) Placebo groups Chinese population oriented trials 11% 10% 9% 9% 6% 6% 7% 7% 7% 7% 6% 5% 5% 5% 5% 4% 3%

  23. Slide 23: Pipeline strategy for autoimmune: leverage science in immunology and antibody engineering

    Pipeline strategy for autoimmune: leverage science in immunology and antibody engineering technology to fulfill unmet medical needs Switching from Traditional to Innovative Targeted Therapies Best-in-Class Drug Candidate for Psoriasis IBI355 (CD40L) Ph1 - SLE Thoughtful Bio-engineer Fc YTE mutation

  24. Slide 24: Pipeline strategy for ophthalmology: accelerate registrational studies for first-in-class bispecific antibody

    Pipeline strategy for ophthalmology: accelerate registrational studies for first-in-class bispecific antibody Accelerate Registrational Studies with Clear Clinical Value IBI302 as Next-gen Bispecific to Target Unmet Need from VEGF Next-generation FIC bispecifics IBI311 (IGF-1R) Potent BCVA gain Ph3

  25. Slide 25: Globalization strategy: achieve global innovation based on in-house antibody engineering and ADC platforms

    Globalization strategy: achieve global innovation based on in-house antibody engineering and ADC platform technologies CEACAM5 CLDN18.2 ADC B7H3 Multi-regional clinical trial TROP2 (MRCT) • Best-in-class signals in early phase China • IO combo in frontline treatment Global market market PD-1/IL-2 Bs

  26. Slide 26: IBI343: potential best-in-class CLDN18.2 - ADC

    IBI343: potential best-in-class CLDN18.2 - ADC Differentiated design for potential wide therapeutic window and high potency Differentiated design for potential best-in-Class profiles Better In-vivo efficacy than MMAE and Dxd Heterogeneous TAA expression Asn297 • World leading ADC technology collabor

  27. Slide 27: IBI343: potential best-in-class CLDN18.2 - ADC

    IBI343: potential best-in-class CLDN18.2 - ADC Preliminary proof-of-concept signals observed in gastric cancer Observed better-than-peer safety at high dose level Preliminary PoC achieved in gastric cancer • Dose escalation reached 10mg/kg. • Dosed over 100 GC/PDAC patients with CLDN18.2 expression.

  28. Slide 28: IBI363 (PD-1/IL-2): highly potent bispecific Fc-fusion protein

    IBI363 (PD-1/IL-2) : highly potent bispecific Fc-fusion protein Enhance IO treatment, including PD-1/PD-L1 resistant/refractory and cold tumors Unique molecular design based on breakthrough findings to enhance antitumor efficacy and reduce toxicity • IL-2α-bias agonists that preserve IL-2Rα (CD25) a

  29. Slide 29: IBI363 (PD-1/IL-2): highly potent bispecific Fc-fusion protein

    IBI363 (PD-1/IL-2) : highly potent bispecific Fc-fusion protein Dose escalation reach unprecedented level and preliminary efficacy observed in IO-failed cancers Phase 1 MRCT ongoing with 200+ patients dosed Durable response in IO-failed cancers and cold tumors pembrolizumab-resistant melanoma Baseli

  30. Slide 30: Healthy financial position and improving financials safeguard business growth

    Healthy financial position and improving financials safeguard business growth through efficient strategy implementation and execution Significantly narrowed EBITDA loss Healthy financial position RMBm Over US$1.5bn * 1,200 Cash and Cash Equivalent 1,036 1,000 800 ↓74.2% yoy 600 400 US$300~400m 267 R

  31. Slide 31: Long-Term Vision

    Long-Term Vision Developing core competiveness 2030 based on strategic vision, global 2025 talent and strong execution • More commercialized • Expanded products, including 2023 commercialized first-in-class products in China blockbusters launched globally • Multiple products launched in the • To be

  32. Slide 32: Disclaimer

    Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu

  33. Slide 33: Confidential

    Confidential Copyright© 2023 Innovent 33

Innovent Biologics — Morgan Stanley's 22nd Annual Asia Pacific Summit (November 2023) on 6ix